The Experts below are selected from a list of 14295 Experts worldwide ranked by ideXlab platform
Yoshio Uehara - One of the best experts on this subject based on the ideXlab platform.
-
Lipid Metabolism and Renal Protection by Chronic Cicletanine Treatment in Dahl Salt-sensitive Rats with Salt-Induced Hypertension
Blood pressure, 1997Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Yasuki Akie, Atsuko Ichikawa, Norio Funahashi, Atsuo Goto, Masao OmataAbstract:Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Coto A, Omata M. Lipid metabolism and Renal Protection by chronic cicletunine treatment in Dahl salt-sensitive rats with salt-induced hypertension.We investigated the role of lipid metabolism in Renal Protection by chronic cicletanine treatment in Dahl salt-sensitive (Dahl S) rats with salt-induced hypertension. Forty-four 6-week old Dahl S rats were divided into four groups: (1) low-salt (0.3% NaC1) control group; (2) high-salt (4% NaC1) control group; (3) low-dose (10mg/kg/day) cicletanine (C1CL)-treated group given a high-salt diet; and (4) high-dose (30 mg/kg/day) cicletanine-treated group given a high-salt diet. The rats were treated for 6 weeks; blood pressure was measured by the tail-cuff method. Cicletanine significantly reduced the systolic blood pressure in a dose-dependent manner (223 mmHg in the high-salt controls vs 195 mmHg in the high-dose, high-salt group, p > 0.01). Cicletanine treatment did not affect plasma concentration o...
-
Vasoconstrictors and Renal Protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Journal of cardiovascular pharmacology, 1994Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Atsushi Numabe, Toshihiko Ishimitsu, Shigeru Yagi, Masao OmataAbstract:We investigated the role of the vasoconstrictors endothelin-1 (ET-1) and thromboxane in Renal Protection by the beta 1-selective adrenoceptor antagonist, bisoprolol, in Dahl salt-sensitive rats (Dahl S) and salt-resistant rats (Dahl R). Six-week bisoprolol treatment (20 mg/kg chow) reduced systolic blood pressure (SBP) by 14% in Dahl S rats fed a high-salt (4% NaCl) diet. This BP reduction was accompanied by a decrease in aortic wall thickness. ET-1 and thromboxane released from Renal cortex was significantly decreased by 17 and 30% with bisoprolol, respectively. Other prostaglandin synthesis was unaffected. Renal function such as proteinuria, N-acetyl-beta-D-glucosaminidase (NAG) excretion, and glomerular filtration rate (GFR) was not influenced by bisoprolol. Morphologic investigation showed that bisoprolol significantly improved glomerular sclerosis by 29% and attenuated arterial damage by 71%, although tubular injury was not affected. The more severe the glomerulosclerotic lesions, the greater the generation of thromboxane and ET. The arterial lesions were positively correlated to thromboxane generation. These data indicate that long-term bisoprolol treatment reduces vasoconstrictive ET-1 and thromboxane generation and that these alterations may be partly responsible for the amelioration of glomerular and arterial injury in Dahl S rats.
-
Antihypertensive property and Renal Protection by Shichimotsu-koka-to extract in salt-induced hypertension in Dahl strain rats
The American journal of Chinese medicine, 1994Co-Authors: Nobuhito Hiwara, Yoshio Uehara, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Toshihiko Ishimitsu, Taiji Nagata, Tomoko Gomi, Toshio IkedaAbstract:We determined whether or not the kampo formula, Shichimotsu-koka-to extract, attenuates the development of salt-induced hypertension and provides Renal Protection against hypertensive injury in Dahl salt-sensitive (Dahl S) rats. A six-week treatment using this formula dose-dependently decreased the systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. This blood pressure reduction was associated with a decrease in the thickness of the aortic wall. Renal function was not altered with this treatment; however, glomerular sclerotic lesions in the kidney were significantly attenuated. Neither arterial nor tubular lesions were affected. These data suggest that Shichimotsu-koka-to extract exhibits an antihypertensive effect which is associated with partial resolution of glomerular sclerosis in the kidney.
-
Radical Scavenging Properties of Indapamide and Renal Protection in Dahl Salt-Sensitive Rats
Hypertension Research, 1992Co-Authors: Yoshio Uehara, Yukari Kawabata, Atsushi Numabe, Hiroaki Shirahase, Katsuo Wada, Yukiko Hashizume, Shigeyoshi Morishita, Junichi Iwai, Hiroaki Matsuoka, Tsuneaki SugimotoAbstract:We have found that indapamide has free radical scavenging properties and stimulates prostacyclin generation in vascular smooth muscle cells. In this study, we investigated whether indapamide exhibits radical scavenging effects in vivo and whether these properties are related to Renal Protection in Dahl salt-sensitive (Dahl S) rats. Indapamide (4mg/kg body weight per day for 5 weeks) ameliorated the development of hypertension in Dahl S rats fed a high salt (6% NaCl) diet. The blood pressure reduction was associated with a decrease in proteinuria, a decrease in urinary n-acetyl-β-D-glucosaminidase excretion, and an increase in glomerular filtration rate. Moreover, morphological investigation revealed improvement in glomerulosclerosis, Renal tubular damage and intraRenal arterial injuries, seen in the salt-induced hypertension. These beneficial properties were accompanied by a significant decrease in the capacity for lipid peroxide formation in the Renal homogenates. In contrast, trichloromethiazide, which reduced the blood pressure to the same extent as indapamide, did not lower lipid peroxide formation in the kidney or exert protective effects on the Renal glomeruli or arteries. Thus, the evidence suggests that the diuretic indapamide exhibits radical scavenging effects on the kidney which may contribute to attenuating the Renal injuries seen in salt-induced hypertension in Dahl S rats. (Hypertens Res 1992; 15: 17-26)
Yukari Kawabata - One of the best experts on this subject based on the ideXlab platform.
-
Lipid Metabolism and Renal Protection by Chronic Cicletanine Treatment in Dahl Salt-sensitive Rats with Salt-Induced Hypertension
Blood pressure, 1997Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Yasuki Akie, Atsuko Ichikawa, Norio Funahashi, Atsuo Goto, Masao OmataAbstract:Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Coto A, Omata M. Lipid metabolism and Renal Protection by chronic cicletunine treatment in Dahl salt-sensitive rats with salt-induced hypertension.We investigated the role of lipid metabolism in Renal Protection by chronic cicletanine treatment in Dahl salt-sensitive (Dahl S) rats with salt-induced hypertension. Forty-four 6-week old Dahl S rats were divided into four groups: (1) low-salt (0.3% NaC1) control group; (2) high-salt (4% NaC1) control group; (3) low-dose (10mg/kg/day) cicletanine (C1CL)-treated group given a high-salt diet; and (4) high-dose (30 mg/kg/day) cicletanine-treated group given a high-salt diet. The rats were treated for 6 weeks; blood pressure was measured by the tail-cuff method. Cicletanine significantly reduced the systolic blood pressure in a dose-dependent manner (223 mmHg in the high-salt controls vs 195 mmHg in the high-dose, high-salt group, p > 0.01). Cicletanine treatment did not affect plasma concentration o...
-
Vasoconstrictors and Renal Protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Journal of cardiovascular pharmacology, 1994Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Atsushi Numabe, Toshihiko Ishimitsu, Shigeru Yagi, Masao OmataAbstract:We investigated the role of the vasoconstrictors endothelin-1 (ET-1) and thromboxane in Renal Protection by the beta 1-selective adrenoceptor antagonist, bisoprolol, in Dahl salt-sensitive rats (Dahl S) and salt-resistant rats (Dahl R). Six-week bisoprolol treatment (20 mg/kg chow) reduced systolic blood pressure (SBP) by 14% in Dahl S rats fed a high-salt (4% NaCl) diet. This BP reduction was accompanied by a decrease in aortic wall thickness. ET-1 and thromboxane released from Renal cortex was significantly decreased by 17 and 30% with bisoprolol, respectively. Other prostaglandin synthesis was unaffected. Renal function such as proteinuria, N-acetyl-beta-D-glucosaminidase (NAG) excretion, and glomerular filtration rate (GFR) was not influenced by bisoprolol. Morphologic investigation showed that bisoprolol significantly improved glomerular sclerosis by 29% and attenuated arterial damage by 71%, although tubular injury was not affected. The more severe the glomerulosclerotic lesions, the greater the generation of thromboxane and ET. The arterial lesions were positively correlated to thromboxane generation. These data indicate that long-term bisoprolol treatment reduces vasoconstrictive ET-1 and thromboxane generation and that these alterations may be partly responsible for the amelioration of glomerular and arterial injury in Dahl S rats.
-
Antihypertensive property and Renal Protection by Shichimotsu-koka-to extract in salt-induced hypertension in Dahl strain rats
The American journal of Chinese medicine, 1994Co-Authors: Nobuhito Hiwara, Yoshio Uehara, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Toshihiko Ishimitsu, Taiji Nagata, Tomoko Gomi, Toshio IkedaAbstract:We determined whether or not the kampo formula, Shichimotsu-koka-to extract, attenuates the development of salt-induced hypertension and provides Renal Protection against hypertensive injury in Dahl salt-sensitive (Dahl S) rats. A six-week treatment using this formula dose-dependently decreased the systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. This blood pressure reduction was associated with a decrease in the thickness of the aortic wall. Renal function was not altered with this treatment; however, glomerular sclerotic lesions in the kidney were significantly attenuated. Neither arterial nor tubular lesions were affected. These data suggest that Shichimotsu-koka-to extract exhibits an antihypertensive effect which is associated with partial resolution of glomerular sclerosis in the kidney.
-
Radical Scavenging Properties of Indapamide and Renal Protection in Dahl Salt-Sensitive Rats
Hypertension Research, 1992Co-Authors: Yoshio Uehara, Yukari Kawabata, Atsushi Numabe, Hiroaki Shirahase, Katsuo Wada, Yukiko Hashizume, Shigeyoshi Morishita, Junichi Iwai, Hiroaki Matsuoka, Tsuneaki SugimotoAbstract:We have found that indapamide has free radical scavenging properties and stimulates prostacyclin generation in vascular smooth muscle cells. In this study, we investigated whether indapamide exhibits radical scavenging effects in vivo and whether these properties are related to Renal Protection in Dahl salt-sensitive (Dahl S) rats. Indapamide (4mg/kg body weight per day for 5 weeks) ameliorated the development of hypertension in Dahl S rats fed a high salt (6% NaCl) diet. The blood pressure reduction was associated with a decrease in proteinuria, a decrease in urinary n-acetyl-β-D-glucosaminidase excretion, and an increase in glomerular filtration rate. Moreover, morphological investigation revealed improvement in glomerulosclerosis, Renal tubular damage and intraRenal arterial injuries, seen in the salt-induced hypertension. These beneficial properties were accompanied by a significant decrease in the capacity for lipid peroxide formation in the Renal homogenates. In contrast, trichloromethiazide, which reduced the blood pressure to the same extent as indapamide, did not lower lipid peroxide formation in the kidney or exert protective effects on the Renal glomeruli or arteries. Thus, the evidence suggests that the diuretic indapamide exhibits radical scavenging effects on the kidney which may contribute to attenuating the Renal injuries seen in salt-induced hypertension in Dahl S rats. (Hypertens Res 1992; 15: 17-26)
Masao Omata - One of the best experts on this subject based on the ideXlab platform.
-
Lipid Metabolism and Renal Protection by Chronic Cicletanine Treatment in Dahl Salt-sensitive Rats with Salt-Induced Hypertension
Blood pressure, 1997Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Yasuki Akie, Atsuko Ichikawa, Norio Funahashi, Atsuo Goto, Masao OmataAbstract:Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Coto A, Omata M. Lipid metabolism and Renal Protection by chronic cicletunine treatment in Dahl salt-sensitive rats with salt-induced hypertension.We investigated the role of lipid metabolism in Renal Protection by chronic cicletanine treatment in Dahl salt-sensitive (Dahl S) rats with salt-induced hypertension. Forty-four 6-week old Dahl S rats were divided into four groups: (1) low-salt (0.3% NaC1) control group; (2) high-salt (4% NaC1) control group; (3) low-dose (10mg/kg/day) cicletanine (C1CL)-treated group given a high-salt diet; and (4) high-dose (30 mg/kg/day) cicletanine-treated group given a high-salt diet. The rats were treated for 6 weeks; blood pressure was measured by the tail-cuff method. Cicletanine significantly reduced the systolic blood pressure in a dose-dependent manner (223 mmHg in the high-salt controls vs 195 mmHg in the high-dose, high-salt group, p > 0.01). Cicletanine treatment did not affect plasma concentration o...
-
Vasoconstrictors and Renal Protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Journal of cardiovascular pharmacology, 1994Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Atsushi Numabe, Toshihiko Ishimitsu, Shigeru Yagi, Masao OmataAbstract:We investigated the role of the vasoconstrictors endothelin-1 (ET-1) and thromboxane in Renal Protection by the beta 1-selective adrenoceptor antagonist, bisoprolol, in Dahl salt-sensitive rats (Dahl S) and salt-resistant rats (Dahl R). Six-week bisoprolol treatment (20 mg/kg chow) reduced systolic blood pressure (SBP) by 14% in Dahl S rats fed a high-salt (4% NaCl) diet. This BP reduction was accompanied by a decrease in aortic wall thickness. ET-1 and thromboxane released from Renal cortex was significantly decreased by 17 and 30% with bisoprolol, respectively. Other prostaglandin synthesis was unaffected. Renal function such as proteinuria, N-acetyl-beta-D-glucosaminidase (NAG) excretion, and glomerular filtration rate (GFR) was not influenced by bisoprolol. Morphologic investigation showed that bisoprolol significantly improved glomerular sclerosis by 29% and attenuated arterial damage by 71%, although tubular injury was not affected. The more severe the glomerulosclerotic lesions, the greater the generation of thromboxane and ET. The arterial lesions were positively correlated to thromboxane generation. These data indicate that long-term bisoprolol treatment reduces vasoconstrictive ET-1 and thromboxane generation and that these alterations may be partly responsible for the amelioration of glomerular and arterial injury in Dahl S rats.
Tomas Berl - One of the best experts on this subject based on the ideXlab platform.
-
Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and Renal Protection: the case for AT1 receptor antagonist.
Journal of the American Society of Nephrology : JASN, 2004Co-Authors: Tomas BerlAbstract:The development of pharmacologic agents that directly inhibit the angiotensin II receptor (angiotensin receptor blocker [ARB]) has provided clinicians with an alternative to the previously available angiotensin-converting enzyme inhibitors (ACEI) to downregulate the renin-angiotensin system. This review focuses on the available data that can guide the clinician to the use of these two classes of agents vis à vis their ability to provide cardiovascular (CV) and Renal Protection. Although the CV protective effect of ACEI in high-risk populations is widely appreciated, whether such an effect is entirely BP independent can be questioned. Most head-to-head comparisons between ACEI and ARB have yielded comparable CV protective effects, with ARB being associated with fewer adverse effects. Likewise, several-but not all-studies have demonstrated a CV protective effect of ACEI when compared with other active agents in patients with type 2 diabetes. One study demonstrated a similar Protection with ARB when compared with a beta blocker. In terms of Renal Protection, there are ample data to support a role for both ACEI and ARB to prevent the progression from microalbuminuria to overt albuminuria in both type 1 and type 2 diabetes. However, when progression of Renal disease is used as an end point, Protection has been demonstrated with ACEI only for type 1 but not type 2 diabetes. In this latter group, only ARB have been shown to slow progression to ESRD.
-
Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist
Journal of the American Society of Nephrology, 2004Co-Authors: Tomas BerlAbstract:ABSTRACT. The development of pharmacologic agents that directly inhibit the angiotensin II receptor (angiotensin receptor blocker [ARB]) has provided clinicians with an alternative to the previously available angiotensin-converting enzyme inhibitors (ACEI) to downregulate the renin-angiotensin system. This review focuses on the available data that can guide the clinician to the use of these two classes of agents vis a vis their ability to provide cardiovascular (CV) and Renal Protection. Although the CV protective effect of ACEI in high-risk populations is widely appreciated, whether such an effect is entirely BP independent can be questioned. Most head-to-head comparisons between ACEI and ARB have yielded comparable CV protective effects, with ARB being associated with fewer adverse effects. Likewise, several—but not all—studies have demonstrated a CV protective effect of ACEI when compared with other active agents in patients with type 2 diabetes. One study demonstrated a similar Protection with ARB when compared with a β blocker. In terms of Renal Protection, there are ample data to support a role for both ACEI and ARB to prevent the progression from microalbuminuria to overt albuminuria in both type 1 and type 2 diabetes. However, when progression of Renal disease is used as an end point, Protection has been demonstrated with ACEI only for type 1 but not type 2 diabetes. In this latter group, only ARB have been shown to slow progression to ESRD.
Atsuo Goto - One of the best experts on this subject based on the ideXlab platform.
-
Lipid Metabolism and Renal Protection by Chronic Cicletanine Treatment in Dahl Salt-sensitive Rats with Salt-Induced Hypertension
Blood pressure, 1997Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Yasuki Akie, Atsuko Ichikawa, Norio Funahashi, Atsuo Goto, Masao OmataAbstract:Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Coto A, Omata M. Lipid metabolism and Renal Protection by chronic cicletunine treatment in Dahl salt-sensitive rats with salt-induced hypertension.We investigated the role of lipid metabolism in Renal Protection by chronic cicletanine treatment in Dahl salt-sensitive (Dahl S) rats with salt-induced hypertension. Forty-four 6-week old Dahl S rats were divided into four groups: (1) low-salt (0.3% NaC1) control group; (2) high-salt (4% NaC1) control group; (3) low-dose (10mg/kg/day) cicletanine (C1CL)-treated group given a high-salt diet; and (4) high-dose (30 mg/kg/day) cicletanine-treated group given a high-salt diet. The rats were treated for 6 weeks; blood pressure was measured by the tail-cuff method. Cicletanine significantly reduced the systolic blood pressure in a dose-dependent manner (223 mmHg in the high-salt controls vs 195 mmHg in the high-dose, high-salt group, p > 0.01). Cicletanine treatment did not affect plasma concentration o...
-
Vasoconstrictors and Renal Protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Journal of cardiovascular pharmacology, 1994Co-Authors: Yoshio Uehara, Nobuhito Hirawa, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Atsushi Numabe, Toshihiko Ishimitsu, Shigeru Yagi, Masao OmataAbstract:We investigated the role of the vasoconstrictors endothelin-1 (ET-1) and thromboxane in Renal Protection by the beta 1-selective adrenoceptor antagonist, bisoprolol, in Dahl salt-sensitive rats (Dahl S) and salt-resistant rats (Dahl R). Six-week bisoprolol treatment (20 mg/kg chow) reduced systolic blood pressure (SBP) by 14% in Dahl S rats fed a high-salt (4% NaCl) diet. This BP reduction was accompanied by a decrease in aortic wall thickness. ET-1 and thromboxane released from Renal cortex was significantly decreased by 17 and 30% with bisoprolol, respectively. Other prostaglandin synthesis was unaffected. Renal function such as proteinuria, N-acetyl-beta-D-glucosaminidase (NAG) excretion, and glomerular filtration rate (GFR) was not influenced by bisoprolol. Morphologic investigation showed that bisoprolol significantly improved glomerular sclerosis by 29% and attenuated arterial damage by 71%, although tubular injury was not affected. The more severe the glomerulosclerotic lesions, the greater the generation of thromboxane and ET. The arterial lesions were positively correlated to thromboxane generation. These data indicate that long-term bisoprolol treatment reduces vasoconstrictive ET-1 and thromboxane generation and that these alterations may be partly responsible for the amelioration of glomerular and arterial injury in Dahl S rats.
-
Antihypertensive property and Renal Protection by Shichimotsu-koka-to extract in salt-induced hypertension in Dahl strain rats
The American journal of Chinese medicine, 1994Co-Authors: Nobuhito Hiwara, Yoshio Uehara, Yukari Kawabata, Atsuo Goto, Satoru Takada, Nobuko Ohshima, Toshihiko Ishimitsu, Taiji Nagata, Tomoko Gomi, Toshio IkedaAbstract:We determined whether or not the kampo formula, Shichimotsu-koka-to extract, attenuates the development of salt-induced hypertension and provides Renal Protection against hypertensive injury in Dahl salt-sensitive (Dahl S) rats. A six-week treatment using this formula dose-dependently decreased the systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. This blood pressure reduction was associated with a decrease in the thickness of the aortic wall. Renal function was not altered with this treatment; however, glomerular sclerotic lesions in the kidney were significantly attenuated. Neither arterial nor tubular lesions were affected. These data suggest that Shichimotsu-koka-to extract exhibits an antihypertensive effect which is associated with partial resolution of glomerular sclerosis in the kidney.
